Related references
Note: Only part of the references are listed.Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment
Huanjie Yang et al.
SEMINARS IN CANCER BIOLOGY (2021)
Old drugs, new uses: Drug repurposing in hematological malignancies
Vijay P. Kale et al.
SEMINARS IN CANCER BIOLOGY (2021)
TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma
Jumpei Teramachi et al.
HAEMATOLOGICA (2021)
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma
Sarah Gooding et al.
BLOOD (2021)
GANT-61 Induces Autophagy and Apoptosis in Glioblastoma Cells despite their heterogeneity
Gabriela Basile Carballo et al.
CELLULAR AND MOLECULAR NEUROBIOLOGY (2021)
Thalidomide Inhibits Angiogenesis via Downregulation of VEGF and Angiopoietin-2 in Crohn's Disease
Lin Wang et al.
INFLAMMATION (2021)
Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy
Shota Yamamoto et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Discovery of indole-3-butyric acid derivatives as potent histone deacetylase inhibitors
Yiming Chen et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2021)
HDAC6 as privileged target in drug discovery: A perspective
Sravani Pulya et al.
PHARMACOLOGICAL RESEARCH (2021)
Discovery of Small-Molecule Antagonists of the PWWP Domain of NSD2
Renato Ferreira de Freitas et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma
M. Heider et al.
MOLECULAR CELL (2021)
USP14 negatively regulates RIG-I-mediated IL-6 and TNF-α production by inhibiting NF-κB activation
Hongrui Li et al.
MOLECULAR IMMUNOLOGY (2021)
Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives
Robert Jenke et al.
CANCERS (2021)
Promising Anti-Mitochondrial Agents for Overcoming Acquired Drug Resistance in Multiple Myeloma
Vanessa Innao et al.
CELLS (2021)
Peptide-Targeted High-Density Lipoprotein Nanoparticles for Combinatorial Treatment against Metastatic Breast Cancer
Chuli Jiang et al.
ACS APPLIED MATERIALS & INTERFACES (2021)
Involvement of Alarmins in the Pathogenesis and Progression of Multiple Myeloma
Giuseppe Murdaca et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
p53 Deacetylation Alleviates Sepsis-Induced Acute Kidney Injury by Promoting Autophagy
Maomao Sun et al.
FRONTIERS IN IMMUNOLOGY (2021)
SMAD1 as a biomarker and potential therapeutic target in drug-resistant multiple myeloma
Jian Wu et al.
BIOMARKER RESEARCH (2021)
Proteasome Inhibitor Drugs
Lloyd D. Fricker
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 60 (2020)
Identification of PIKfyve kinase as a target in multiple myeloma
Cecilia Bonolo de Campos et al.
HAEMATOLOGICA (2020)
Carfilzomib, venetoclax and dexamethasone for relapsed/refractory multiple myeloma
Clementine Boccon-Gibod et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Venetoclax: the first anti-myeloma agent with a reliable biomarker
Tomas Jelinek
BRITISH JOURNAL OF HAEMATOLOGY (2020)
SOX12 promotes the growth of multiple myeloma cells by enhancing Wnt/β-catenin signaling
Ying Gao et al.
EXPERIMENTAL CELL RESEARCH (2020)
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma
Eric K. Rowinsky et al.
INVESTIGATIONAL NEW DRUGS (2020)
The deubiquitinase USP7 stabilizes Maf proteins to promote myeloma cell survival
Yuanming He et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
Maria-Victoria Mateos et al.
LANCET (2020)
Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2020)
Discovery of [1,2,3]triazolo[4,5-d]pyrimidine derivatives as highly potent, selective, and cellularly active USP28 inhibitors
Zhenzhen Liu et al.
ACTA PHARMACEUTICA SINICA B (2020)
Proteasome Inhibitors for the Treatment of Multiple Myeloma
Shigeki Ito
CANCERS (2020)
Inhibition of USP9X Downregulates JAK2-V617F and Induces Apoptosis Synergistically with BH3 Mimetics Preferentially in Ruxolitinib-Persistent JAK2-V617F-Positive Leukemic Cells
Hiroki Akiyama et al.
CANCERS (2020)
The novel cereblon modulator CC-885 inhibits mitophagy via selective degradation of BNIP3L
Bing-bing Hao et al.
ACTA PHARMACOLOGICA SINICA (2020)
Design and synthesis of new lenalidomide analogs via Suzuki cross-coupling reaction
Donghuai Xiao et al.
ARCHIV DER PHARMAZIE (2020)
Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial)
Juan C. Ramos et al.
BLOOD (2020)
The Wee1 kinase inhibitor MK1775 suppresses cell growth, attenuates stemness and synergises with bortezomib in multiple myeloma
Long Liang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t (4;14)-positive multiple myeloma
Chee Man Cheong et al.
CANCER LETTERS (2020)
Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism
Nathan J. Schauer et al.
SCIENTIFIC REPORTS (2020)
The Role of Deubiquitinating Enzymes in Hematopoiesis and Hematological Malignancies
Neha Sarodaya et al.
CANCERS (2020)
Discovery of novel USP8 inhibitors via Ubiquitin-Rho-110 fluorometric assay based high throughput screening
Jie Han et al.
BIOORGANIC CHEMISTRY (2020)
MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma
Qiang Wang et al.
BLOOD (2020)
Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma
Saeko Kuwahara-Ota et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
PIKing the next therapeutic target in multiple myeloma
Jessica L. Caro et al.
HAEMATOLOGICA (2020)
A Gli inhibitor GANT61 suppresses cell proliferation, promotes cell apoptosis and induces G1/G0 cycle retardation with a dose- and time-dependent manner through inhibiting Notch pathway in multiple myeloma
Zhihua Zhang et al.
CELL CYCLE (2020)
XPO1-dependent nuclear export as a target for cancer therapy
Nancy G. Azizian et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Protein homeostasis from the outside in
Brant M. Webster et al.
NATURE CELL BIOLOGY (2020)
Molecular mechanisms of thalidomide and its derivatives
Takumi Ito et al.
PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES (2020)
PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia
Justyna M. Gawel et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
SR18292 exerts potent antitumor effects in multiple myeloma via inhibition of oxidative phosphorylation
Yu Xiang et al.
LIFE SCIENCES (2020)
The role of ubiquitination and deubiquitination in cancer metabolism
Tianshui Sun et al.
MOLECULAR CANCER (2020)
Targeting Nuclear Export Proteins in Multiple Myeloma Therapy
Nicholas Theodoropoulos et al.
TARGETED ONCOLOGY (2020)
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
Maria-Victoria Mateos et al.
BLOOD CANCER JOURNAL (2020)
A Cereblon Modulator CC-885 Induces CRBN- and p97-Dependent PLK1 Degradation and Synergizes with Volasertib to Suppress Lung Cancer
Lifeng Li et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
Degradation of Intrinsically Disordered Proteins by the NADH 26S Proteasome
Peter Tsvetkov et al.
BIOMOLECULES (2020)
BRD4 inhibitor nitroxoline enhances the sensitivity of multiple myeloma cells to bortezomib in vitro and in vivo by promoting mitochondrial pathway-mediated cell apoptosis
Guang Li et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2020)
The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma
Xiaoyang Sun et al.
BIOSCIENCE REPORTS (2019)
Off-target effects of carfilzomib that cause cardiotoxicity
Jan S. Moreb
BLOOD (2019)
A Practical Review of Proteasome Pharmacology
Tiffany A. Thibaudeau et al.
PHARMACOLOGICAL REVIEWS (2019)
WP1130 Enhances TRAIL-Induced Apoptosis through USP9X-Dependent miR-708-Mediated Downregulation of c-FLIP
Seok Kim et al.
CANCERS (2019)
Gli Proteins: Regulation in Development and Cancer
Pawel Niewiadomski et al.
CELLS (2019)
Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later
Pawel Robak et al.
DRUGS IN R&D (2019)
MPT0G413, A Novel HDAC6-Selective Inhibitor, and Bortezomib Synergistically Exert Anti-tumor Activity in Multiple Myeloma Cells
Fang- Huang et al.
FRONTIERS IN ONCOLOGY (2019)
Mebendazole elicits potent antimyeloma activity by inhibiting the USP5/c-Maf axis
Xue-han Chen et al.
ACTA PHARMACOLOGICA SINICA (2019)
Preparation and biological evaluation of soluble tetrapeptide epoxyketone proteasome inhibitors
Meng Lei et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2019)
Emerging protein kinase inhibitors for the treatment of multiple myeloma
Judith Lind et al.
EXPERT OPINION ON EMERGING DRUGS (2019)
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau et al.
LANCET (2019)
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Paul G. Richardson et al.
LANCET ONCOLOGY (2019)
Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations
Richard W. Birkinshaw et al.
NATURE COMMUNICATIONS (2019)
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma
Laura Rosinol et al.
BLOOD (2019)
Is the Fate of Clinical Candidate Arry-520 Already Sealed? Predicting Resistance in Eg5-Inhibitor Complexes
Rose-Laure Indorato et al.
MOLECULAR CANCER THERAPEUTICS (2019)
The role of CXCR4 in multiple myeloma: Cells' journey from bone marrow to beyond
Tomalika Rahmat Ullah
JOURNAL OF BONE ONCOLOGY (2019)
Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines
Rebecca S. S. Barbosa et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2019)
Bioinspired manganese complexes catalyzed epoxidation for the synthesis of the epoxyketone fragment of carfilzomib
Bin Qiu et al.
CHINESE CHEMICAL LETTERS (2019)
Ixazomib - the first oral proteasome inhibitor
Jingmei Xie et al.
LEUKEMIA & LYMPHOMA (2019)
DPP8 is a novel therapeutic target for multiple myeloma
Tsutomu Sato et al.
SCIENTIFIC REPORTS (2019)
Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
Graham H. Jackson et al.
LANCET HAEMATOLOGY (2019)
Immunomodulatory drugs in the treatment of multiple myeloma
Yu Abe et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2019)
A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies
Drew W. Rasco et al.
CLINICAL CANCER RESEARCH (2019)
Deubiquitinating enzymes as cancer biomarkers: new therapeutic opportunities?
Naresh Poondla et al.
BMB REPORTS (2019)
A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos
Mary E. Matyskiela et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma
Kyriaki Tzogani et al.
ONCOLOGIST (2018)
Histone deacetylase 5 (HDAC5) regulates neuropathic pain through SRY-related HMG-box 10 (SOX10)-dependent mechanism in mice
Pan Gu et al.
PAIN (2018)
Chemical, computational and functional insights into the chemical stability of the Hedgehog pathway inhibitor GANT61
Andrea Calcaterra et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2018)
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo
Hsueh-Yun Lee et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
The regulation of FOXO1 and its role in disease progression
Ya-qi Xing et al.
LIFE SCIENCES (2018)
Global Burden of Multiple Myeloma ASystematic Analysis for the Global Burden of Disease Study 2016
Andrew J. Cowan et al.
JAMA ONCOLOGY (2018)
Novel isatin-derived molecules activate p53 via interference with Mdm2 to promote apoptosis
Olga Fedorova et al.
CELL CYCLE (2018)
Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial
Niels W. C. J. van de Donk et al.
LANCET HAEMATOLOGY (2018)
Ubiquitin ligases in oncogenic transformation and cancer therapy
Daniela Senft et al.
NATURE REVIEWS CANCER (2018)
Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia
Xiaoyan Wu et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2017)
Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair
Ana-Alicia Lopez-Iglesias et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors
Jin-Yi Zhu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Proteasome Structure and Assembly
Lauren Budenholzer et al.
JOURNAL OF MOLECULAR BIOLOGY (2017)
USP7 small-molecule inhibitors interfere with ubiquitin binding
Lorna Kategaya et al.
NATURE (2017)
Proteasome inhibitors in cancer therapy
Elisabet E. Manasanch et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Discovery of novel BET inhibitors by drug repurposing of nitroxoline and its analogues
Hao Jiang et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2017)
Active site-targeted covalent irreversible inhibitors of USP7 impair the functions of Foxp3+T-regulatory cells by promoting ubiquitination of Tip60
Feng Wang et al.
PLOS ONE (2017)
Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
Fraser Aird et al.
ELIFE (2017)
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
Shaji Kumar et al.
BLOOD (2017)
Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells
Deepika Sharma Das et al.
CLINICAL CANCER RESEARCH (2017)
USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status
Angelo Agathanggelou et al.
BLOOD (2017)
Selective Chemical Inhibition of PGC-1α Gluconeogenic Activity Ameliorates Type 2 Diabetes
Kfir Sharabi et al.
CELL (2017)
A Set of Activity-Based Probes to Visualize Human (Immuno)proteasome Activities
Gerjan de Bruin et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
Syed Abbas Ali et al.
BLOOD (2016)
SnapShot: Types of Ubiquitin Ligases
Francesca Ester Morreale et al.
CELL (2016)
Histone deacetylase 3 (HDAC 3) as emerging drug target in NF-κB-mediated inflammation
Niek G. J. Leus et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2016)
Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial
Sonoko Misawa et al.
LANCET NEUROLOGY (2016)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)
A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells
D. S. Das et al.
LEUKEMIA (2016)
The Role of PGC1α in Cancer Metabolism and its Therapeutic Implications
Zheqiong Tan et al.
MOLECULAR CANCER THERAPEUTICS (2016)
A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase
Mary E. Matyskiela et al.
NATURE (2016)
Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma
Teru Hideshima et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies
Luke F. Peterson et al.
BLOOD (2015)
Molecular basis of resistance to proteasome inhibitors in hematological malignancies
Denise Niewerth et al.
DRUG RESISTANCE UPDATES (2015)
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
H. M. Lokhorst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Type 2 diabetes as a protein misfolding disease
Abhisek Mukherjee et al.
TRENDS IN MOLECULAR MEDICINE (2015)
Degrasyn-like symmetrical compounds: Possible therapeutic agents for multiple myeloma (MM-I)
Zhenghong Peng et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2014)
MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells
Yanyan Gu et al.
BLOOD (2014)
Endoplasmic Reticulum Stress in Malignancy
Hanna J. Clarke et al.
CANCER CELL (2014)
From Anecdote to Targeted Therapy: The Curious Case of Thalidomide in Multiple Myeloma
Jonathan D. Licht et al.
CANCER CELL (2014)
Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma
Sridurga Mithraprabhu et al.
EPIGENETICS (2014)
Disturbance of endoplasmic reticulum proteostasis in neurodegenerative diseases
Claudio Hetz et al.
NATURE REVIEWS NEUROSCIENCE (2014)
Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs
Philip P. Chamberlain et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2014)
PGC-1a integrates glucose metabolism and angiogenesis in multiple myeloma cells by regulating VEGF and GLUT-4
Dedong Cao et al.
ONCOLOGY REPORTS (2014)
Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights
Prithviraj Bose et al.
PHARMACOLOGY & THERAPEUTICS (2014)
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Jan Kroenke et al.
SCIENCE (2014)
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Gang Lu et al.
SCIENCE (2014)
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Jakob Loven et al.
CELL (2013)
Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells
J. Etchin et al.
LEUKEMIA (2013)
From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes
Kyung Bo Kim et al.
NATURAL PRODUCT REPORTS (2013)
The resistance mechanisms of proteasome inhibitor bortezomib
Shuqing Lu et al.
BIOMARKER RESEARCH (2013)
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
Loredana Santo et al.
BLOOD (2012)
Discovery of Specific Inhibitors of Human USP7/HAUSP Deubiquitinating Enzyme
Celine Reverdy et al.
CHEMISTRY & BIOLOGY (2012)
Next-generation proteasome inhibitor approved in multiple myeloma
Alla Katsnelson
NATURE BIOTECHNOLOGY (2012)
Pathogenesis of Myeloma
Kenneth C. Anderson et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 6 (2011)
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Yuan Xiao Zhu et al.
BLOOD (2011)
In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells
Dharminder Chauhan et al.
CLINICAL CANCER RESEARCH (2011)
Inhibitors of Apoptosis Proteins (IAPs) as Potential Molecular Targets for Therapy of Hematological Malignancies
P. Smolewski et al.
CURRENT MOLECULAR MEDICINE (2011)
Evidence of a Role for Activation of Wnt/β-Catenin Signaling in the Resistance of Plasma Cells to Lenalidomide
Chad C. Bjorklund et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia
Rekha Pal et al.
BLOOD (2010)
Mcl-1 Stability Determines Mitotic Cell Fate of Human Multiple Myeloma Tumor Cells Treated with the Kinesin Spindle Protein Inhibitor ARRY-520
Brian J. Tunquist et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Substrate-Assisted Inhibition of Ubiquitin-like Protein-Activating Enzymes: The NEDD8 E1 Inhibitor MLN4924 Forms a NEDD8-AMP Mimetic In Situ
James E. Brownell et al.
MOLECULAR CELL (2010)
Design, Synthesis, Biological Evaluation, and Structure-Activity Relationship (SAR) Discussion of Dipeptidyl Boronate Proteasome Inhibitors, Part I: Comprehensive Understanding of the SAR of α-Amino Acid Boronates
Yongqiang Zhu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Teresa A. Soucy et al.
NATURE (2009)
FRESH FROM THE PIPELINE Plerixafor
John F. DiPersio et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Bcl-2-family proteins and hematologic malignancies: history and future prospects
John C. Reed
BLOOD (2008)
Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally
Yu Zhang et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
20S proteasome and its inhibitors: Crystallographic knowledge for drug development
Ljudmila Borissenko et al.
CHEMICAL REVIEWS (2007)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Structural bioinformatics-based design of selective, irreversible kinase inhibitors
MS Cohen et al.
SCIENCE (2005)
Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors
T Rasmussen et al.
BLOOD (2005)
Proteasome inhibitors: from research tools to drug candidates
AF Kisselev et al.
CHEMISTRY & BIOLOGY (2001)
Share Paper
